AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference

May 7, 2019

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2019--Ironwood Pharmaceuticals, Inc.  (NASDAQ: IRWD) will present a corporate update at the 2019 Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 14, 2019 at 8:00 a.m. Pacific Time at The Encore Hotel in Las Vegas.

A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). We are currently advancing a Phase IIIb trial evaluating the efficacy and safety of linaclotide on multiple abdominal symptoms, including pain, bloating and discomfort, in adult patients with IBS-C.

We are also advancing two late-stage, first-in-category GI product candidates: IW-3718 is a gastric retentive formulation of a bile acid sequestrant being developed for the potential treatment of persistent gastroesophageal reflux disease, and MD-7246 is a delayed-release formulation of linaclotide that is being evaluated as an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with IBS with diarrhea.

Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit our newly launched website at www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190507005782/en/

CONTACT: Meredith Kaya, 617-374-5082

Vice President, Investor Relations and Corporate Communications

mkaya@ironwoodpharma.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEVADA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Ironwood Pharmaceuticals, Inc.

Copyright Business Wire 2019.

PUB: 05/07/2019 04:05 PM/DISC: 05/07/2019 04:05 PM

http://www.businesswire.com/news/home/20190507005782/en

All contents © copyright 2019 The Associated Press.All rights reserved.